[Short bowel syndrome. GLP-2 analog teduglutide].
Medizinische Klinik II der Ludwig-Maximilians-Universität München Klinikum Grosshadern, Marchioninistrasse 15, 81377 München. martin.storr@gmx.de
Martin
M
Storr
D000222:Adaptation, Physiological / Q000187:drug effects / Q000502:physiology; D000328:Adult; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005440:Fluid Therapy; D005858:Germany; D053767:Glucagon-Like Peptide 2 / Q000378:metabolism*; D006801:Humans; D007279:Injections, Subcutaneous; D007413:Intestinal Mucosa / Q000187:drug effects / Q000503:physiopathology; D015337:Multicenter Studies as Topic; D010288:Parenteral Nutrition; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012778:Short Bowel Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D053767:Glucagon-Like Peptide 2; D010455:Peptides; C494910:teduglutide